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INTRODUCTION
1INTRODUCTION
Liver failure can develop acutely in a patient with no preexisting liver disease
(acute liver failure) or as an acute decompensation of a chronic liver disease.
Recently it has been noted that a subgroup of patients develops acute
deterioration in previously compensated cirrhosis and are considered to have
acute on chronic liver failure (ACLF). This deterioration is secondary to an acute
event and multi organ failure leading to increased mortality at three months.
In contrast to chronic liver disease these patients have a rapid downhill course
with the development of multiorgan failure and high short term mortality. One
important concept in this group of patients is the potential reversibility. The
term reversibility does not mean that underlying chronic liver damage is
reversible, but rather the acute deterioration of the liver function due to the
precipitating event is reversible.  The pathophysiological basis ACLF was
initially described by Jalan et al [1]. There is no clear cut definition of ACLF in
the western literature. Asia Pacific association of study of liver (APASL) has
defined it as acute hepatic insult manifested by jaundice and coagulopathy
complicated within four weeks by ascites or encephalopathy [2]. The cause for
acute deterioration can vary from infectious causes like sepsis, viral hepatitis
and non hepatotrophic viruses’ infection or noninfectious causes like alcohol,
drugs, gastrointestinal bleeding, toxins and surgery.  There is controversy
2regarding  whether  sepsis  can  precipitate  ACLF  or  it  is  the  result  of  ACLF.
Though numerous studies have been published in western literature on
cirrhotic patients admitted to ICU, most of them have not differentiated organ
failure  as  part  of  progressive  worsening  in  end  stage  cirrhosis  from  acute  on
chronic liver failure [10, 15, 17, and 18]. There are very few studies from India
in this subject. H Garg et al have recently published a prospective study on
ACLF patients [9]. Etiology of chronic liver disease and the acute precipitants
differ between various geographical locations. AS ACLF carries a high mortality
it is essential to identify prognostic factors. In general it has been noted that
score evaluating the severity of disease like APACHE and SOFA score are better
than liver specific score like Child Pugh score[18.20,21].  Management of ACLF
requires good intensive care to prevent the development of organ failure or to
support the failing organs. Use of various extracorporeal liver support systems
have been studied in various studies[14,25-28].Even though there is an
improvement in biochemical parameters and in hepatic encephalopathy ,there
is no significant survival benefit. Liver transplantation is the only curative
treatment [29].
This prospective study aims to look at the clinical profile, precipitating factors,
outcome prognostic factors in ACLF admitted in a tertiary care hospital.
AIM OF THE STUDY
3AIM OF THE STUDY
The aims of the study are as follows
1. To study the clinical profile of patients with acute on chronic liver failure
2. To study the underlying chronic aetiology and acute precipitants
3. To study the 30 day and 90 day mortality
4. To study the various predictors of mortality
REVIEW OF LITERATURE
4REVIEW OF LITERATURE
Cirrhosis occurs due to a wide spectrum of hepatocellular insults and it is rarely
reversible. Once initiated, it progresses from a compensated state to
decompensated state resulting in morbidity and mortality. These complications
are the direct result of the impaired liver function that is due to a decreased
functional capacity of the hepatocyte mass and the architectural distortion
that impairs normal hepatic blood flow. Liver transplantation is the only
curative treatment.
Recently a subgroup of patients with chronic liver disease has been identified
who have acute downhill course in a previously compensated liver disease due
to an acute insult. This clinical entity has been termed as acute on chronic liver
failure (ACLF). It is characterized by rapidly developing liver failure due to an
identifiable precipitating event leading to increased short term mortality due
to multi organ failure. There is an element of reversibility when identified
early.
5Definition
Asia pacific Association of study of liver diseases (APASL) consensus guidelines
and the working definition by EASL-AASLD on ACLF is given in table 1[2, 3]
End stage vs. acute on chronic liver failure
Cirrhosis is the last phase of a progressive parenchymal cell damage leading to
nodular parenchymal regeneration and progressive fibrosis. Liver insufficiency
occurs due to progressive hepatocyte loss .When the hepatocytes reach below
a critical functional liver cell mass liver failure sets in (figure 1).
6There is a substantial overlap between the clinical presentation of end stage
and acute on chronic liver failure .These include jaundice, hepatic
encephalopathy or
Hepatorenal syndrome. But ACLF is characterized the element of reversibility
and an acute   precipitating event in most of them. In addition most patients
7progress towards multi organ failure and have high short term mortality. So
ACLF refers to acute deterioration of liver function by a precipitating event
which is subsequently followed by other organ failure whereas ‘end stage liver
disease’ refers to a chronically decompensated state due to progressive
deterioration of the underlying liver disease.
ACLF must also be differentiated from acute or fulminant liver failure which
occurs in patients without any evidence of preexisting liver disease. Cerebral
edema is a prominent feature of acute liver failure. AASLD defines acute liver
failure as the presence of coagulopathy and encephalopathy in patient with no
preexisting liver disease with disease duration of less than 26 weeks.
Why this interest in ACLF?
Increasing interest in ACLF in recent years is due to two reasons. First is the
Consideration of Model for End-stage Liver Disease-(MELD) score (based on
serum bilirubin, serum creatinine and International normal ratio) for allotting
organs in liver transplantation. This score predicts the 3 month mortality.
Before the implementation of MELD donor organs were allotted on the basis of
waiting time. But after the implementation of MELD sickest patients get
priority, so ACLF patients get an opportunity to receive an organ based on
severity of the disease.
8Second reason for the increasing interest is the potential for reversibility and
the need for use of liver support devices. In end stage liver disease only liver
transplant can cure the patient. In ACLF management of acute precipitating
event (e.g. anti-viral in Hepatitis B activation) can bring the patient back to
previous critical liver cell mass. Additionally use of liver support devices can be
considered to give time for the liver to recover or as bridge to transplantation.
Reversibility
Reversibility is the main component of ACLF [43, 44]. The term ‘reversibility’
here does not mean that cirrhosis is reversible, but rather that there is a
component of acute deterioration that is reversible. Jalan et al have studied a
large group of cirrhotic patients hospitalized for various complications [5]. They
noted a mortality of 53% which indicates that reversibility in half the patients.
What is not known is the degree to which reversibility can occur. Reversibility
does not mean just survival, but rather return to baseline function.
Precipitating event
This is the second important component of ACLF.There is an identifiable
precipitating event in ACLF. This is in contrast to end stage liver disease where
there is continued hepatocellular damage leading to worsening of disease. This
9new ‘acute’ insult may or may not be related to original etiology of the
underlying chronic liver disease. But experts agree that the acute precipitating
event should be of hepatic origin [2]. For example it could alcoholic hepatitis
on a preexisting alcoholic liver disease or super added acute viral hepatitis E in
alcoholic liver disease. The reversibility depends on the severity and nature of
acute insult and degree of underlying chronic liver disease.
These acute precipitating events can be infectious or noninfectious (Figure2
and table 2). There is a difference between the west and the east in the major
etiological agents. Viral infections are more common in the east whereas
alcohol and drugs are more common in the west [15, 18-20].
Among infectious causes reactivation hepatitis B virus infection is one of the
major cause of ACLF. This reactivation can be spontaneous or due to
immunosuppression, cancer chemotherapy or immune restoration due.to
highly active antiretroviral therapy. Another important infectious cause of
reactivation is acute hepatitis E. Prevalence of acute hepatitis E in ACLF varies
from 13-21% [6, 7].various bacterial,spirochetal and fungal infections can also
affect the liver.
Among the noninfectious causes alcoholic hepatitis is a common cause of
acute deterioration. Other causes include drug induced liver injury and intake
of native or herbal medications.
10
Sepsis is an important component of ACLF and its outcome. Most western
studies have included sepsis as a precipitating event. But this is controversial
and it has
been argued that sepsis can worsen the condition, but by itself it cannot
directly cause a hepatic insult. APASL guidelines have not included sepsis as an
acute precipitant.
Acute variceal bleeding is one of the features of decompensation in the natural
history of cirrhosis. Variceal bleeding has been included as one the acute
precipitants of ACLF in some western studies. Variceal bleed is an expression of
elevated portal pressure and is not due to an acute insult. However no
consensus has been reached in APASL regarding including variceal bleed as an
acute insult.
Table 2 Precipitating events in ACLF
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Major surgical procedures can also lead to acute deterioration in a patient with
cirrhosis. However there is a conflicting opinion among experts about including
surgery as an acute insult or not. According to APASL guidelines surgery can be
include as an acute insult if the clinical syndrome otherwise fits the current
definition.
In some patients in spite of best evaluation acute precipitant may not be
found.
Hitendra Garg et al have done large prospective study on ACLF patients. In
their study hepatitis B was the most frequent cause of underlying disease.
Alcohol was the second common cause. Etiology of underlying disease was not
known in about a quarter of patients. Common acute precipitant was Hepatitis
Figure 2 Precipitating events in ACLF
12
B reactivation in underlying chronic hepatitis B (85%) and super added
alcoholic hepatitis (81%) in alcoholic liver disease. In 14% of them had hepatitis
E was identified as acute precipitant.
In  a  retrospective  study  by  Duseja  et  al  alcohol  was  the  most  common
etiology(61%) followed by cryptogenic (14%) and other causes which include
hepatitis B ,hepatitis c, autoimmune, and Wilson disease[41].
ROLE OF SEPSIS
Sepsis is an important component ACLF. There is controversy regarding
including sepsis as an acute precipitant in ACLF.APASL guidelines does not
include sepsis as an acute event. How can sepsis precipitate liver failure? It has
been suggested that lipopolysaccharide (LPS) found in bacteria produces liver
injury by inducing apoptosis and also by ischemic injury due to accompanying
circulatory disturbances. The apoptotic effect of LPS is augmented by the
release of Tumor necrosis factor (TNF) [1]. However it has been argued that
sepsis alone cannot directly cause liver injury, but can worsen the condition of
the patient.
Microorganism-associated molecular patterns (MAMPs)-induced
proinflammatory response leads to widespread inflammation, multi organ
13
failure, and death [45]. Organ failure is due to tissue hypo perfusion and
hypoxia. Hypo perfusion is due to decreased perfusion pressure and flow,
micro thrombi formation, reduced red blood cell deformability, blood mal
distribution, and tissue edema caused by increased capillary permeability. In
addition, cells may be unable to properly utilize available oxygen due to
impairment in mitochondrial respiration in part due to nitric oxide (NO)
overproduction. Finally, cellular infiltrates, in particular neutrophils, damage
tissue directly by releasing lysosome enzymes and superoxide-derived free
radicals.
14
PATHOPHYSIOLOGY
The main pathophysiological mechanisms involved in ACLF are the presence of
Systemic Inflammatory Response syndrome (SIRS), release of cytokines,
neutrophil dysfunction and altered nitric oxide levels. What tilts the balance
from well compensated state to ACLF is the deregulated inflammation due to
altered host response to injury. The ‘Toxin hypothesis’ was considered to be
Figure 3-Mechanism for sepsis induced liver failure; MAMPs-Microorganism-
associated molecular patterns,PRRs-pattern recognition receptors
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main mechanism leading to organ failure in ACLF (Figure 4). The Toxin
hypothesis suggests there is accumulation of toxins due to impaired hepatic
detoxification and metabolism.The toxins are usually albumin like aromatic
amino acids, mercaptans, ammonia, and nitric oxide [8].
Although toxin accumulation is an important factor, at present
pathophysiology of ACLF is considered to be much more complex. Bacterial
translocation (BT) also plays an important role in its pathogenesis. Bacterial
translocation occurs due to increases intestinal permeability and is frequently
seen in cirrhotics. In 30-50% of patients with cirrhosis infection is the cause for
admission [9].How ever bacterial translocation alone is not enough to explain
the organ dysfunction. It has to be accompanied by abnormal immune
response and vascular hyperreactivity due to inflammatory cytokines(figure
5).The degree of BT is related to degree of underlying liver disease than to the
portal hypertension(PHT) itself. This is evidenced by increasing prevalence of
BT with increasing CTP scores[30].
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Mechanisms of immune dysfunction in ACLF
Immune dysfunction or immune paralysis is a significant component in
cirrhosis [38]. Decreased synthetic function of liver leads to decreased
opsonisation capacity (figure 6). Opsonisation is important for bacterial
phagocytosis. Another important cause of immune dysfunction is the portal
hypertension. Kuppfer cell is a component of reticulo endothelial system (RES).
Because of the shunting of blood in collaterals the bacteria evade the RES and
enter systemic circulation [10]. Phagocytic activity of mononuclear cells and
neutrophils are impaired. There is
17
Increased production of TNF ? which means that immune system though
dysfunctional is in a persistently activated state. Activated kuppfer cells
produce huge amount of cytokines, chemokines and oxygen derived free
radicals (figure 7). These include interleukin (IL)-1, IL-17, IL-18, and TNF ? [32].
 Presence of bacteria and their toxins leads to activation of inflammatory
cascade and the sepsis syndrome. This inflammatory cascade is responsible for
the features of SIRS. The hyper dynamic circulation of cirrhosis is further
aggravated by this unbalanced immune response .So perfusion to vital organs
is affected. Ischemia aggravates the organ injury kidneys and brain and finally
multi organ failure and death is produced.
18
Figure 5 Role of Bacterial Translocation in ACLF
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Clinical implications of immune dysfunction
The main implication of immune dysfunction in ACLF is that infection is
common in them. This has been demonstrated in various studies as follows:
Infection is a cause for hospital admission in 15-35% of cirrhotics in contrast to
5-10% in general population. Secondly various therapeutic interventions has
been tried to modify this immune response. Corticosteroids and
pentoxyfylline, an inhibitor of TNF ? have been used in severe acute alcoholic
hepatitis
Figure 6 Immune dysfunction of ACLF
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.
Figure 8 Role of cytokines in ACLF
Figure 7 Role of Activated Kuppfer cells in ACLF
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PIRO concept in ACLF
A concept similar to PIRO (Predisposition, Injury, Response and Organ failure)
concept in sepsis has been proposed in ACLF.Predisposition is indicated by the
severity of the underlying illness. Injury is indicated by the nature and severity
of the precipitating event. Response is defined by host response to injury,
which determines the severity of inflammation and risk of   infection. Organs
indicate the extent of organ failure. Categorizing the patients into these
entities helps us to define the interventions and prognosis at different levels.
NATURAL HISTORY AND PROGNOSIS
There is limited data on natural history of cirrhosis progressing to organ failure
and its outcome. In a study by Jalan et al. 497 cirrhotic patients admitted with
acute deterioration mortality was 8% in those without organ failure whereas it
was 53% in those with organ failure [5]. Increasing number of organ failures is
associated with worse prognosis. Time from organ failure to death was 10(1-
40) days. Mortality was higher (78%) in those with recent decompensation in
previous 6 months than in those without (34%).Changes in SOFA scores
improved sensitivity and specificity in predicting mortality. Irrespective of the
precipitant presence of SIRS significantly predicted mortality. There have been
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very few prospective studies which have looked into the natural history of
ACLF. Most of the studies that have been published vary in their inclusion
criteria as different definitions of ACLF are used in west and east.
Many prognostic factors that determine the outcome in ACLF have been
studied. In general scoring systems pertaining to severity of  liver disease such
asChild-Pugh  score  or  Model  of   End  Stage  Liver  Disease  (MELD)  do  less  well
than the scoring systems used in critically ill patients like the Sequential Organ
Failure Assessment SOFA) or the Acute Physiology, Age and Chronic Health
Evaluation (APACHE)scores. In fact once organ failure has begun mortality is
determined by the severity of the organ failure and not by the severity of the
liver disease [17-21].
Katoonizadeh et al in their prospective study on early features acute on
chronic liver failure in alcoholic liver disease compared patients with ACLF with
chronic decompensated cirrhosis [12]. They found an in-hospital mortality of
46% in ACLF in contrast to an in-hospital mortality of 10% in chronic
decompensated cirrhosis. Early signs of infection, positive systemic
inflammatory response syndrome at admission and ductal stasis of bilirubin
were early markers of ACLF. This was the first prospective cohort study
attempting to characterize acute on chronic liver failure.
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In the study by H Garg et al 29% had organ failure at admission [9]. By one
week 46% had developed organ failure. Number of organ failure correlated
with hospital mortality-it was 26% in those with only one organ failure and
>90% in those with four or more organ failures. The 30 day and 90 day
mortality was 50% and 63% respectively. Presence of hepatic encephalopathy,
high WBC count, low platelets, low serum sodium, high serum creatinine, large
varices  and  high  HVPG  were  found  to  be  associated  with  mortality.  But  on
multivariate analysis only hepatic encephalopathy, low serum sodium and high
INR were found to be predictors of mortality.MELD, SOFA and APACHE-II, had
better predictability than CTP in predicting mortality.
In the systemic review published by Wlodzimirow et al in Liver International,
they have done tried to identify various prognostic markers from all the studies
published on ACLF[25].They have concluded that there is underlying
differences between various studies making comparison difficult. Age, hepatic
encephalopathy, model for end-stage liver disease score, total bilirubin and
International normalized ratio (prothrombintime) are considered to promising
markers for future evaluation.
European Consortium on Chronic Liver Failure (CLIF) has done large multi
centric prospective observational study (CANONIC) on Acute on Chronic liver
failure [13]. The main aim of this study is to define the natural history of ACLF
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and evaluate the prevalence, precipitating mechanisms, and risk factors for its
development, survival and the risk factors of mortality. Preliminary data was
presented in the International liver congress in 2012 and has reported a
mortality of 35.5% in contrast to only 4.5% in those without ACLF. It was
significantly associated with bacterial infections and active alcoholism. No
precipitating cause was found in about 20 %.Four grades of ACLF were
identified by them
? ACLF-1: renal failure or a non-renal organ failure associated with
creatinine 1.5-2 mg/dL and/or grade I-II encephalopathy
? ACLF-2: 2 organ failures
? ACLF-3: 3 organ failures
? ACLF-4: 4-6 organ failures
This would be one the largest prospective studies on ACLF and would help us
to better define and prognosticate the disease.
MANAGEMENT OF ACLF
The key point in the management of ACLF in contrast to the management of
chronic end stage liver disease is the identification of the precipitating event
and prevention and management of multi organ failure. Organ failure is seen
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as part of gradual deterioration in end stage liver disease and only curative
option is liver transplantation. However in ACLF if the liver damage due to the
acute precipitant is reversible prognosis is better. Due consideration should be
given to prevention of infections and organ dysfunction. This can be done by
judicious use of antibiotics, fluid, albumin and vasopressors.
Spontaneous reactivation of chronic hepatitis b is a common cause of ACLF.
Short term mortality ranges from 30-40% [33-35].liver transplantation is
curable but it is inaccessible to most. Antivirals have tried. Tenofovir is a potent
nucleotide analog which has been used in chronic hepatitis B. In a study
byGarg etal 27 patients of ACLF were randomized to receive tenofoviror
placebo [36]. Tenofovir has improved the mortality from 15%to57%. Among
the survivors there is not only a significant decline in HBVDNA levels but also
an  improvement  in  severity  scores  like  CTP  and  MELD.  More  than  two  log
reduction in HBVDNA levels within two weeks was associated with better
survival.
Ribavirin has been tried for acute hepatitis E in ACLF in small number of
patients. In a study from AIIMS,Delhi [37] four patients with genotype 1 acute
HEV in ACLF were treated with 200-600mg/day ribavirin for 3-24 weeks
(median 12 weeks).All the patients had survived and had cleared the virus by
3-8 weeks.
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Another novel therapy that has been used in ACLF is granulocyte colony
stimulating factor (G-CSF). It was initially used by Di Campilli et al [39] and it
was shown to induce stem cell mobilization. Ina randomized study by Garg et
al 47 patients of ACLF were randomized to receive 5ug/kg G-CSF or placebo in
addition to standard medical treatment[40]. Survival was 66%in the treatment
group and 26% in the placebo group. Improvement in severity scores was
better in the treatment group. Also the number of complications like
hepatorenal syndrome, hepatic encephalopathy and sepsis was lower. It acts
by mobilization of CD34 stem cells from bone marrow.
Role of liver transplantation
The recent increasing interest in ACLF is due to the use of MELD for organ
allocation. With the use of MELD sickest patients get priority and hence many
of the patients with ACLF can get transplanted. There are very few studies on
liver transplantation in ACLF. Albert Chan et al [30] have described their series
of 149 patients who underwent liver transplantation for ACLF. Two third of
them were due to chronic hepatitis B. Their 5 year survival was more than 90%,
similar to the results obtained by other indications. Indications for liver
27
transplant is based on the prognostic scores which suggest death within the
next three months[2].Patients who are hemodynamically unstable and are on
large dose of vasopressors, severe infections and cerebral edema or
intracranial bleeding are not candidates for liver transplant.
Role of liver support devices in ACLF
Artificial liver support devices play an important role in supporting the liver till
it recovers or as a bridge to liver transplantation. Molecular adsorbent
recirculating system (MARS) has been studied widely. In MARS, blood is
dialyzed across
An albumin-impermeable membrane with a molecular weight cut-off of 50 to
60 kDa against 20% human serum albumin, which is continuously stripped by
subsequent passage through columns of charcoal and an anion exchange resin.
Water-soluble substances are removed by a low-flux dialyzer connected to the
secondary circuit. Prometheus separates the patient’s own albumin/plasma by
a membrane with a molecular weight cut-off of 300 kDa and directly passes it
over two columns containing different adsorbents. Water-soluble substances
are cleared by a high-flux dialyzer directly inserted into the blood circuit.
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In RELIEF trial conducted in Spain patients with ACLF were randomized to
MARS or to standard medical therapy [14]. MARS had an acceptable safety
profile, decrease in creatinine and bilirubin. The most consistent benefit has
been seen with improvement of hepatic encephalopathy.  It is efficient in
removing cytokines. However no survival benefit could be demonstrated. Role
of MARS as a bridge to transplantation still needs to be defined. So at present
it is not routinely used in the treatment of ACLF.
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MATERIALS AND METHODS
This prospective study was conducted in Department of Medical
gastroenterology, Rajiv Gandhi Government General Hospital, Chennai. The
study period was from November 2011 to February 2013. Consecutive patients
of acute on chronic liver failure were enrolled.
Inclusion criteria
Consecutive patients with ACLF as defined by APASL guidelines in Table 1 were
included- Patients complicated by ascites and encephalopathy within four
weeks of onset of jaundice (bilirubin >5 mg/dl) and coagulopathy (INR >1.5)
.These patients can have either previously diagnosed or undiagnosed
compensated chronic liver disease. Patients are considered to have chronic
liver disease by the presence of any of the following –nodular contracted liver
on ultrasound, portal vein ?13 mm, and oesophageal varices ?2 on endoscopy
or fibrosis ? 2 on histology [9].
Exclusion criteria
1. Hepatocellular carcinoma
2. Portal vein thrombosis
3. Patients with any disseminated malignancy
4. HIV
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5. Pregnant women
6. Age less than 18 years or more than 80 years
Data collection
Data was collected prospectively on patient’s demographics, clinical features,
laboratory parameters, disease severity, aetiology of the underlying chronic
disease and the acute insult, presence of multi organ dysfunction and
outcome.
Clinical profile and course
Once a diagnosis of ACLF has been made data was collected prospectively on
patient demographics, clinical symptoms and signs, laboratory parameters,
complications and outcomes. Extensive history was taken from the patients
and the attending relatives. This included history of alcohol intake, other drugs
including native medications, abdominal distension, fever, altered sensorium,
upper gastrointestinal bleed and risk factors for viral hepatitis.
All patients underwent detailed physical examination and vital signs were
recorded. Presence of spiderneavi,   gynaecomastia, hepatomegaly, ascites,
abdominal wall collaterals and grade of encephalopathy was noted. Hepatic
encephalopathy was graded according to West Haven system into grade 0 to 4.
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 Blood was collected for complete blood count, urea, creatinine, electrolytes,
liver function tests, prothrombin time, INR,   C - reactive protein and viral
markers. All the parameters were repeated every 1-3 days depending on the
severity of the illness. Ascitic fluid analysis was done for Serum ascitic fluid
albumin gradient, cell count and culture. Spontaneous bacterial peritonitis was
defined by the presence of > 250 neutrophils per mm3 or positive ascitic fluid
cultures .Blood cultures were sent in all patients and other body fluids were
sent for cultures when clinically indicated.
All patients  under went USG abdomen and PV Doppler study and following
details were recorded- Liver span, surface nodularity of liver, Size of the
spleen, size of  portal and splenic veins; presence of portal-systemic collaterals,
presence of ascites .
Upper gastrointestinal endoscopy was done to document the grade of varices.
Esophageal varices were classified according to grading system by Paquet as
given in table. Presence of gastric varices and portal hypertensive gastropathy
were noted.
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In  HBs  Ag  positive  patients  samples  were  sent  for  HBV  DNA  levels,  HB  e  Ag,
Anti HBc IgM and total. In Patients positive for HCV samples were sent for HCV
RNA levels and genotype. Patients positive for anti HEV IgM were considered
to having acute hepatitis E.
Assessment of severity and organ dysfunction
Following severity scores were calculated for all patients-Child –Turcotte-Pugh
(CTP),  MELD  and  modified  SOFA  score  (Table  5  and  6    ).  MELD  score  is
calculated as follows -logarithmic equation (0.957 × log [creatinine mg/dl] +
0.378 × log [bilirubin mg/dl] + 1.120 × log [international normalized ratio] +
0.643) Presence or absence of Systemic Inflammatory response syndrome
(SIRS)  was  noted  (Table  4    ).  Maddrey's  Discriminant  function  (MDF)  was
calculated in patients who had alcoholic liver disease as follows: [4.6 ×
Table 3 Paquet Classification of oesophageal varices
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(patient’s prothrombin time ? control prothrombin time, in seconds)] + serum
bilirubin level, in milligrams per deciliter. These scores were calculated at
baseline and also repeated at weekly intervals. Organ failure was defined by
the  presence  of  SOFA  score  of  3  or  more  for  the  respective  organ  system.
Presence of two or more extra hepatic organ failure is defined as multiorgan
failure.
Table 4 SIRS (Systemic Inflammatory Response Syndrome) criteria
34
Table 5 Child-Pugh-classification
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SOFA SCORE 0 1 2 3 4
RESPIRATION
PaO2/FIO2
(mm Hg)
>400 ?400 ?300 ?200 ?100
pulse
oximeter
oxygen
saturation
(SpO2)*
SpO2 >90%
at room air
SpO2
?90%
at room
air,
increased
above
90%
with FiO2
0.24
(1 l/min
nasal
O2)
SpO2 ?90% at
room air,
increased
above 90%
with
FiO2 0.30
(mask)
SpO2 ?90% at room
air,
increased above
90%
with FiO2 0.50
(mask)
SpO2 ?90% at room
air and despite FiO2
0.50 (mask)
COAGULATION
Platelets ×
103/mm3
>150 ?150 ?100 ?50 ?20
LIVER
Bilirubin
(mg/dl)
<1.2 1.2–1.9 2.0–5.9 6.0–11.9 >12.0
CARDIOVASCULAR
Hypotension
No
hypotension
MAP <70
mm Hg
Dopamine ?5
or dobutamine
(any dose)
Dopamine >5 or
epinephrine ?0.1 or
norepinephrine
?0.1
Dopamine >15 or
epinephrine >0.1 or
norepinephrine
>0.1
CENTRAL NERVOUS SYSTEM
Glasgow
Coma Score
15 13–14 10–12 6–9 <6
RENAL
Creatinine
mg/dL <1.2 1.2–1.9 2.0–3.4 3.5–4.9 >5.0
??mol/L) or
urine output
(<110) (110–170) (171–299)
(300–440) or <500
mL/day
(>440) or <200
mL/day
Respiratory failure is defined by a SOFA score ?3 or requirement for mechanical
ventilation; hematologic failure by a score of 4 and/or INR >2.5; liver failure by a score of 4;
cardiovascular failure by a score ?2;neurologic failure by a West Haven score ?3 or requirement for
endotracheal intubation to prevent aspiration pneumonia; renal failure by a score ?2 or requirement for
renal-replacement therapy.
Table 6 Modified SOFA (Sequential Organ Failure score score)
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Statistical analysis
All the data were entered on a excel sheet. Mean and median were calculated
for appropriate variables. All the variables between survivors and non-
survivors or transplanted patients were compared. Variables significant by
univariate analysis were again compared by multivariate analysis. P value less
than 0.05 was taken as significant. Statistical analysis was done by SPSS 16
software.
RESULTS
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RESULTS
During the study period, 57 patients presenting with clinical picture suggestive
of  acute  on  chronic  liver  failure  were  screened.  Of  these  12  patients  were
excluded due to following reasons –presence of hepatocellular carcinoma
(3),portal vein thrombosis (2),patients left against medical advice (5) and no
evidence of chronic liver disease(2).So totally 45 patients were enrolled for the
study. There were forty two males and three females (male: female 14:1).The
mean age of presentation is 42 years (range18-70 years) (figure 9,10 &
Table.7).
42
3
Figure 9  Sex distribution of patients
Males
Females
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Table.7: Age distribution
Age in years No. of cases Percent
? 20 2 4.4
21 - 30 5 10.8
31 - 40 11 24.4
41 - 50 15 33.3
51 - 60 10 22.2
61 - 70 2 4.4
Total 45 100.0
2
5
11
15
10
2
0
2
4
6
8
10
12
14
16
<= 20 21 - 30 31 - 40 41 - 50 51 - 60 61 - 70
No. of patients
No. of cases
Figure 10 Age distribution of patients
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Clinical features and laboratory findings
Acute onset of jaundice with ascites was seen in all the patients. Most patients
had severe jaundice with a median of 15.8 mg/dl (range5.28-
38).Encephalopathy was seen in 18 (40%) patients at admission. During the
hospital stay another 12 patients (total 30 patients i.e. 66% developed
encephalopathy). Out of this 30, 12 patients had grade 2 encephalopathy and 9
patients had grade 3 or more encephalopathy (Table 10 and figure 11).
13 patients (28.9%) had history of gastrointestinal bleeding in the form of
hematemesis or melena. 5 of these patients developed bleeding in the form of
melena after admission and it was probably related to the
coagulopathy.Endoscopy was done in most patients (41).It was not done in the
rest of them because of hemodynamic instability. Most (28 patients -62 %))
had grade 2 or more esophageal varices.27 (60%) patients had portal
hypertensive gastropathy
13 (28.9%) patients had hepatomegaly and 28 (62.2 %) had splenomegaly.2 of
the patients had spider neavi and 2 had parotid enlargement.
The median hemoglobin was 9 gm./dl (range 4.3-13).The median platelets
were 102000/cu mm(8000-321000).Median AST and ALT values were 137 and
40
118 IU/L .Median albumin values were low 2.9gm/dl(1.8- 3.9). INR was
prolonged (median 1.94, Range 1.5-4.5). INR was more than 2.5 in 11 patients
(24%).
100 100
66
47
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20
40
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120
Figure 11 Clinical features of patients
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Table 10 Baseline clinical features of 45 patients
Clinical feature Number Percentage
Median Age (years) 42 19-70
Males 42 93
Jaundice 45 100
Ascites 45 100
Mean duration of symptoms(days) 21 Range (7-28)
Encephalopathy 30 66
Grade ?2 encephalopathy 21 47
Upper GI bleeding 13 28.9
Grade 2 or more esophageal varices 28 79%
Portal hypertensive gastropathy 27 62
Hepatomegaly 13 28.9
Splenomegaly 28 62.2
Spidernaevi 2 4.4
Parotid enlargement 2 4.4
Presence of SIRS 34 75.5
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Table 11: Baseline Laboratory findings of all the patients
Parameter Median Range
WBC(cells/cu mm) 14400 580-26200
HB (gm./dl) 9 4.30-13
Platelets (cell/cu mm) 102000 8000-321000
RBS(mg/dl) 98 40-266
Urea(mg/dl) 38 12-199
Creatinine (mg/dl) .95 0.60-4.5
Sodium(meq/L) 134 115-145
K+(meq/L) 3.90 2.30-5.9
Bilirubin(mg/dl) 15.70 5.28-39
AST(IU/dl) 137 45-350
ALT(IU/dl) 118 24-1642
Proteins(g/dl) 5.60 3.60-6.6
albumin(g/dl) 2.90 1.8-3.9
PT(sec) 23.90 17.0-45
INR 1.94 1.50-4.5
CRP(mg/dl) 48 6-238
MDF 67.30 40.2-128
MELD 26 18-40
SOFA 6 3-14
CTP 12 9-14
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Infection in ACLF
23 patients (51%) had history of fever. Most patients had elevated WBC count
with a median of 14400 (range 580-26200) cells/mm3. (Figure 12& 13)However
infection could be documented in only in 14 (31%) patients. 5(11.1%) patients
had spontaneous bacterial peritonitis .Blood cultures were positive in 3
patients, ascitic fluid cultures in 3 and urine culture  in 2 patients . Klebsiella is
the most common organism isolated followed by pseudomonas and E.coli.
Other foci of infection include pneumonia (2), cellulitis (2) and peri anal
abscess (1).All these patients had signs of sepsis at admission except one. One
patient developed pneumonia after admission. Apart from this, one patient
had parvovirus induced aplastic anemia. Among the patients with documented
sepsis 6 patients survived and 7 died. All patients had elevated CRP except 4
(9%).Median values was 24 mg/dl (range 6-238)
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Figure 13 Different types of infections in ACLF
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Aetiology of liver disease
Aetiology of chronic liver disease and reasons for acute exacerbation was
evaluated. Most common cause of underlying liver disease is alcoholic liver
disease (64.5%) followed by hepatitis B (20%). (Table.12 & Figure.14) Among
the alcoholic liver disease super added alcoholic hepatitis is the most common
(82%) cause followed by acute hepatitis E (4.4%). Most patients were actively
drinking alcohol almost till few days before admission. Among patients with
chronic hepatitis B, reactivation of hepatitis B is the most common cause
followed by hepatitis E and alcohol. There were two patients with autoimmune
liver disease and two patients with hepatitis C in who cause for acute
deterioration could not be found. In two patients with Wilsons disease cause
for acute deterioration was due to drug induced liver disease in one patient
and in another patient cause was not known. Among women 2 patients had
autoimmune hepatitis and one had Wilson’s disease. Overall etiology of
chronic liver disease could not be found in one patient and reason for acute
exacerbation could not be found in 8(17.5%) patients.
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Table 12 Etiology of chronic liver disease and reason for acute deterioration
Etiology of CLD (number) Reason for acute
deterioration
Number(percent)
Alcohol (29) Alcohol
HEV
unknown
24(82.7)
2(4.4)
3(6.6)
Hepatitis B(9) Reactivation
Alcohol
HEV
6(66.6)
2(22.2)
1(11.1)
Autoimmune (2) Unknown 2 (100)
HCV (2) Unknown 2(100)
Wilson (2) DILI
Unknown
1(50)
1(50)
Unknown (1) DILI 1(20)
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Mortality and Prognostic factors
 13 patients died within 30 days .So 30 day mortality was 29%(13/45) another 5
patient died in the next two months and two patients were referred for
transplantation. So the expected 90 day mortality was 44.4 %(20/45). All the
patients died due to multi organ failure except two patients who died due intra
cerebral hemorrhage. One patient with Wilson’s developed intracerebral
hemorrhage due to aplastic anemia and severe thrombocytopenia. The cause
for aplastic anemia was parvovirus infection. The mean time from hospital
admission to death was 22.2 days (3-80). Three (6.6%) patients died within first
29
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Figure 14 Etiology of chronic liver disease
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week and another 5 patients died (11.1%) in the second week. 8 of the 20
patients (40%) died within the initial two weeks. This shows that initial two
weeks is very critical in the management of these patients.One patient with
Wilson’s disease with super added DILI and another patient with chronic
hepatitis B and superadded acute hepatitis E were referred for liver
transplantation.
Significant event in patients with ACLF is the development of organ failure. All
the patients were admitted with liver failure manifested by coagulopathy.
Features of SIRS were present in 34(75%) of patients at admission. Presence of
two or more extra hepatic organ failures was considered to be multiorgan
failure. 11 (24%) had multi organ failure at admission  while another 9(20%) of
them developed  after admission. Mortality was significantly related to the
number of organ failures (Figure.15). Mortality was 7% when there was single
organ failure and 33% with two organ failure whereas it was 90% with three
organ failure. There was 100% mortality with four or more organ failure.
Patients with hepatic encephalopathy were treated with lactulose and bowel
wash. Patients with alcoholic hepatitis were treated with pentoxyfylline and
those with reactivation of hepatitis B were given anti virals. SBP was treated
with third generation cephalosporin and albumin. Antibiotics used in most
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infections were third generation cephalosporin which was changed according
to the culture and sensitivity.
Renal parameters were elevated (creatinine >1 mg/dl) in 17(38%) patients.
Causes include prerenal uremia and hepatorenal syndrome. They were treated
with fluids albumin and terlipressin. Renal replacement therapy was required
100
93
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Figure 15   Number of organ failures and mortality
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in 15 (33.3%) patients.9 patients were mechanically ventilated for hypoxemia
and another 6patients were ventilated for airway protection. Vasopressors
were started when mean arterial pressure was less than 65 mm Hg.
All baseline clinical and biochemical parameters were compared to assess the
possible predictors of mortality. Survivors had grade 1 or no encephalopathy
whereas non survivors had grade 2 or more encephalopathy. Non survivors
were found to have elevated WBC count, low platelet count, elevated
creatinine, low sodium, higher bilirubin, prolonged PT and INR and higher CRP
(table 13). On multivariate analysis platelets, grade 2 or more encephalopathy,
high CRP and Meld score were found be significantly associated with mortality.
The ability of various scoring systems like SOFA score, MELD and CTP score was
assessed to predict mortality between survivors and nonsurvivors using area
under receiver operating curve. AUROC was significantly higher for SOFA and
MELD (.897 and .910) score compared to CTP score (.724)
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Table 13 Comparison of various laboratory parameters and severity scores in
survivors and non survivors
Parameter Survivors
(n=24)
Death or
transplantation
(n=20)
P value
WBC(cells/cu mm) 12500 17200 0.006
HB (gm./dl) 9 8.60 0.426
Platelets (cell/cu mm) 132000 85000 <0.001
RBS(mg/dl) 101 96.00 0.959
Urea(mg/dl) 28 52.00 <0.001
Creatinine (mg/dl) .90 1.10 <0.001
Sodium(meq/L) 136 130 <0.001
K+(meq/L) 3.90 3.90 0.603
Bilirubin(mg/dl) 12.00 24.70 <0.001
AST(IU/dl) 135.00 168 0.004
ALT(IU/dl) 95.00 123 0.189
Proteins(g/dl) 5.80 5.50 0.010
albumin(g/dl) 2.90 2.90 0.722
PT(sec) 20.90 26 <0.001
INR 1.74 2.38 <0.001
CRP(mg/dl) 24.00 96 <0.001
MDF 60.35 83.80 <0.001
MELD 23.00 32.00 <0.001
SOFA 4.00 7.00 <0.001
CTP 11.00 12 0.089
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Figure 16 ROC for SOFA score
Area Under the Curve
Test Result Variable(s):SOFA
Area Std. Error Asymptotic Sig.b
Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
.897 .032 .000 .834 .961
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Figure 17 ROC for MELD score
Area Under the Curve
Test Result Variable(s):SOFA
Area Std. Error Asymptotic Sig.b
Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
.897 .032 .000 .834 .961
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Figure 18 ROC for CTP score
Area Under the Curve
Test Result Variable(s):CTP
Area Std. Error Asymptotic Sig.b
Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
.724 .055 .000 .617 .832
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DISCUSSION
This is a prospective study which looks into the clinical profile, outcome,
precipitating factors and prognostic factors in acute on chronic liver failure.
ACLF is a unique entity which defers from chronic decompensation of an end
stage liver disease with a rapidly deteriorating presentation and a potential for
reversibility. High mortality is mainly due to multiorgan failure. As defined by
APASL guidelines all our patients had jaundice and coagulopathy.  Jaundice was
severe in most patients .Ascites was seen in all patients, but encephalopathy
was  seen  in  63%.Higher  grades  of  encephalopathy  was  more  common  in
nonsurvivors. About a third of patients had previous history of chronic liver
disease.
The most common cause of chronic liver disease in our study is alcoholic liver
disease (64.5%). This can be because alcohol is also the commonest cause
chronic decompensated liver disease in our department. Most western studies
have shown alcohol as the most common etiology followed by viral hepatitis
[8, 10].  Patients with alcoholic liver disease are more prone for infection and
its complications.It has been observed by Mookerjee et al that these patients
have defective neutrophil function and phagocytosis [16]. These neutrophils
show increased oxidative burst which means there is a functional failure. In a
large prospective study by H Garg et al from Delhi chronic hepatitis B followed
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by alcohol and cryptogenic was the common causes [[9]. Duseja et al from
Chandigarh found alcohol as the most common insult followed by viral
hepatitis and autoimmune hepatitis [41]. Our hospital being a tertiary care
center offering a completely free treatment to patients there is a possibility for
referral bias in alcoholic being the most common cause.
Alcohol was the most common acute precipitant in alcoholics in our study.
Most of our patients have been actively drinking almost till a few days before
admission. They were managed by pentoxyfylline in addition to other routine
treatment. Hepatitis B reactivation is the most common cause of acute
deterioration in chronic hepatitis B. Our findings were similar to findings
published in other studies [9, 41] they were started on antivirals.In contrast to
other studies acute hepatitis E is the cause of deterioration in only 3(7%)
patients. In a study from Acharya et al  from Delhi published in 2007  HEV was
positive in 50% of patients with acute deterioration[48].Most studies from
Indian subcontinent  have found acute hepatitis E in 40-60% of patients[49-51].
However these studies cannot be directly compared as the diagnosis of ACLF
has not been clearly defined.
In two patients with underlying chronic hepatitis C the reason for acute
worsening could not be found out. Transaminases were not elevated and HCV
RNA levels low. One patient had severe community acquired pneumonia with
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ARDS requiring ventilator support. Another patient had no significant history
except for blood transfusion outside prior to admission which was followed by
jaundice and ascites.There was no evidence for hemolysis.
One third of our patients had gastrointestinal bleeding, though all had only
mild to moderate bleeding. All the patients had bleeding only after the
development of jaundice and 5 of them developed after admission only. Most
patients had grade 2 varices and portal hypertensive gastropathy.  There is a
controversy regarding including gastrointestinal bleeding as an acute
precipitant [27].In APASL guidelines no consensus has been reached about
including gastrointestinal bleeding as an acute event. Based on the
observations from our study we can say bleeding was probably due to
coagulopathy and stress in most patients and was indicative of sicker patients
rather than as trigger for acute deterioration.
 Sepsis is important component of ACLF.  But whether it is the cause or the
result of ACLF is not clear. Patients with chronic liver disease are more prone
for infection due increased intestinal permeability leading to bacterial
translocation [30]. This bacterial translocation alone is not enough for the
rapid downfall. This is combined with defective immune response in the form
of abnormal neutrophil function and phagocytosis [8] .Half of our patients had
history of fever and almost all the patients had elevated WBC count. Even
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though these two features are suggestive of sepsis, infection could be
documented in only a third of our patients. Spontaneous bacterial peritonitis is
the most common site of infection. Other sites include urinary tract infection,
pneumonia, cellulitis and perianal abscess. Most of our patients are referred
here after partially treating outside and are invariably on antibiotics by the
time they come to us. This could explain the low culture positivity. Other cause
of fever in our patients could be alcoholic hepatitis. Most patients had
elevated CRP and values were significantly higher in patients who did not
survive. So high CRP values especially, persistently elevated values is a poor
prognostic marker.
One of the important features of ACLF is the development of organ failure.
Presence of two or more extra hepatic organ failures is considered to be multi
organ failure. 20 (44%) patients had multi organ failure in our study. 11(24%)
had multi organ failure at admission and another 9(20%) of them developed
after admission. This shows that once inflammatory cascade sets in it is not
always possible to stop it and indicates the severity of underlying disease
which leads to progressive organ failure...  Mortality was significantly related
to number of organ failures. Mortality was significantly related to the number
of  organ failures.   Mortality  was  7% when there was  single  organ failure  and
33% with two organ failure whereas it was 90% with three organ failure. There
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was 100% mortality with four or more organ failure. So as the number of organ
failure increase mortality also increases. This correlation has been shown
previously published studies [9, 20]]
Out of 45 patients, 18 patients died in our study and two patients were
referred for transplantation bringing the expected mortality to 44.4%. This is
similar to mortality in other published studies. However it is lesser than the
mortality seen in the study by H Garg.The mean time from hospital admission
to death was 22.2 days (3-80). Three (6.6%) patients died within first week and
another 5 patients died (11.1%) in the second week. 8 of the 20 patients (40%)
died  within  the  initial  two  weeks.  This  shows  that  initial  two  weeks  is  very
critical in the management of these patients. This importance of initial two
weeks has been highlighted in other studies. If the precipitating can be
controlled or the organ failures can be prevented in the first two weeks
prognosis of the patients can be improved. Two patients were referred for liver
transplantation. First patient was having Wilson’s disease with drug induced
liver injury. She was transplanted seven weeks after admission. Second patient
was having chronic hepatitis B with acute hepatitis E. He was transplanted ten
weeks after admission. Both of them underwent live donor liver transplant.
Both of them are doing well now.
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In our study following factors were significantly associated with mortality-
lower platelets, presence of renal failure, low serum sodium, high serum
bilirubin, prolonged PT, INR and CRP. On multivariate analysis low platelets,
Grade 2 or more encephalopathy, MELD score and high CRP were found to be
independent predictors of death.
Various prognostic scores have been used to assess the severity of disease in
critically ill liver disease patients. It has generally been shown that MELD and
SOFA scores are better predictors of mortality than Child score and APACHE
score [  ].We have not  used APACHE score as  it  is  very  cumbersome to  use at
bedside because of numerous variables and certain parameters like ABG is not
always available at bedside. In our study area under ROC is higher for MELD
and SOFA than CTP demonstrating that MELD score and SOFA score are more
sensitive than CTP score in predicting mortality.
CONCLUSION
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CONCLUSION
Acute on chronic liver failure is a unique entity. It is characterized by rapidly
deteriorating course in a previously diagnosed or undiagnosed chronic liver
disease with a potential for reversibility.
Our study shows that it has high short term mortality (44%). Most common
aetiology for underlying chronic liver disease in our centre is alcoholic liver
disease (64.5%) followed by hepatitis B (20%) and other causes.  The most
common acute precipitant is super added alcoholic hepatitis (82%) in alcoholic
liver disease and reactivation of hepatitis B (66%) in chronic hepatitis B. Other
causes of acute worsening include acute hepatitis E and drug induced liver
injury.Most common cause of death is the multi organ failure. Increasing
number of organ failures is associated with increasing risk of death. High serum
bilirubin, high INR, renal failure,low sodium, and high CRP are all poor
prognostic markers. SOFA and MELD are better predictors of mortality than
Child score. Early referral for liver transplantation is essential in patients at
high risk of death.
Acute on chronic liver failure is a disease which is still being defined and large
prospective studies are needed to better delineate the acute precipitants and
the prognostic markers.
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ABBREVIATIONS
ACLF Acute on Chronic Liver Failure
APASL Asia Pacific Association of Study of Liver
APACHE Acute Physiology and Chronic Health Assessment
BT Bacterial Translocation
CRP C-Reactive Protein
CTP Child Turcott Pugh
EASL European Association of Study of Liver
INR International Normalised Ratio
IL Interleukin
MDF Maddrey’s Discriminant Function
MELD Model for End stage Liver Disease
MARS Molecular Adsorbent Recirculating System
RES Reticulo Endothelial System
SIRS Systemic Inflammatory Response Syndrome
SOFA Sequential Organ Failure Assessment
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ACUTE ON CHRONIC LIVER FAILURE PROFORMA
Name IP no D.O.A
Age + Unit D.O.Discharge
D.O.Death
Sex Ward Duration of
stay
Address Diagnosis
Phone No.
History
Jaundice Altered sensorium
Abdominal
Distension
Hematemesis
Pedal enema Melena
Oliguria Weight loss
Puffiness of face Spontaneous
bleeding
Fever Muscle cramps
Anorexia Cough
fatigue breathlessness
Constipation
Diarrhea
Native medication
Past h/o jaundice Tattooing
Diabetes Blood transfusion
Smoking Drug abuse
Alcohol
Duration
gm/day
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Examination
HE grade Clubbing PR
Nutrition Cyanosis RR
Height Parotid
swelling
Temp
Weight Gynaecomastia BP Systolic
BMI Palmar
erythema
Diastolic
Anaemia Scrotal
swelling
Pulse
pressure
Icterus Skin changes Neck veins
Pedal edema Abd veins CVS
Ascites Back veins RS
Umbilical
hernia
Caput
medusae
Splenomegaly Hepatomegaly
Investigation
USG Abdomen
Liver Size
Echoes
Ascites
Spleen
Endoscopy
PV Doppler CXR
CRP
Ascitic fluid culture
Colour
SAAG
Cell count
PROCALCITONIN
Blood culture
CTP Urine culture
MELD HBsAg Steroids
MDF HCV pentoxyfylline
SOFA Anti HEV Terlipressin
HRS HIV Albumin
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Date
TC
Hb
Platelet
RBS
Urea
Creatinine
Sodium
Potassium
Bilirubin TOT
Direct
Indirect
SGOT
SGPT
ALP
Protein
Albumin
globulin
PT
INR
ABG
lactate
N
am
e
ag
e
Se
x
A/
D
Ja
un
di
ce
D
ur
at
io
n
as
ci
te
s
en
ce
ph
al
op
at
hy
G
ra
de
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ve
r
U
G
IB
Al
c.
 U
se
Hepatomegaly SPlenomegaly
W
BC H
B Pl
t
R
BS
U
re
a
C
re
at
N
a
Bi
li
AM 52 M A Y 8 Y Y 3 N N N N N 10900 10.4 10000 110 27 1.3 136 5.7
AN 50 M A Y 28 Y N 0 Y N Y N N 10900 9.5 299000 134 39 0.9 139 21.3
ANDRAI 46 M A Y 10 Y N 0 Y Y Y N Y 16800 7.7 284000 113 26 0.8 137 9.2
BN 46 M A Y 20 Y Y 3 Y N N N Y 23000 7.6 85000 121 96 2.1 137 21.7
CS 38 M A Y 25 Y Y 1 Y N Y Y Y 14300 9.1 87000 82 38 1.1 136 24.9
EI 55 M A Y 25 Y Y 2 N N Y N N 7000 12.7 100000 40 36 0.7 122 18.9
ER 35 M A Y 27 Y Y 1 Y Y Y Y N 19200 8.5 78000 96 46 1 134 15.6
GS 42 M A Y 20 Y Y 1 N N Y N Y 17610 10.1 208000 83 23 0.8 130 12
HI 30 M A Y 15 Y N 0 N Y Y N N 10600 10.7 147000 103 22 0.7 131 15.5
JPH 42 M A Y 28 Y Y 1 N N Y N Y 15800 4.3 132000 88 28 0.9 136 24
KN 34 M A Y 28 Y N 0 N N Y Y N 8100 9 166000 80 20 0.7 136 8.5
KPN 55 M A Y 20 Y N 0 N N Y Y N 17500 7.4 100000 108 20 0.8 137 8
MI 53 M A Y 20 Y N 0 N N N Y N 7900 12.7 207000 92 28 1 136 9.7
NA 22 F A Y 25 Y Y 2 Y N N y y 22,000 8.6 90000 140 38 0.9 134 33
PL 60 M A Y 20 Y Y 0 Y N N N N 12500 11.2 75000 106 35 0.9 139 15.6
RU 42 M A Y 14 7 Y 2 N Y Y N Y 23,000 5.6 8000 96 64 1.2 137 26.4
RA 32 F A Y 22 Y Y 1 Y N Y N Y 12300 10.3 140000 98 32 0.9 139 8.2
RMN 70 M A Y 15 Y N 0 N Y N N Y 9600 6 95,000 76 36 0.9 125 35
RMSH 44 M A Y 7 Y Y 2 Y N Y N Y 10100 7.3 110000 101 22 0.8 121 5.28
SVN 25 M A Y 20 Y Y 2 Y Y Y N Y 14100 6.3 102000 62 88 2 131 6.4
SKR 52 M A Y 15 Y Y 2 N N Y N Y 6200 7.7 141000 141 22 0.7 145 6.3
SLM 35 M A Y 15 Y N 0 N N Y Y N 11500 8.5 266000 80 20 0.7 145 10.7
SRYA 38 M A Y 14 Y N 0 N N Y Y Y 12500 8 150000 102 40 1 135 8.2
VKTN 28 M A Y 28 Y N 0 Y N Y Y Y 26200 10 120000 165 12 0.6 138 15.7
VKTH 36 M A Y 28 Y Y 1 Y N Y Y Y 14900 9.9 321000 133 75 1.3 134 24.2
AUTN 44 M D Y 20 Y Y 3 Y N Y Y N 15900 4.6 77000 151 21 0.6 119 11.3
CJVI 46 M D Y 25 Y N 0 N N Y N Y 12500 11.9 65000 138 41 0.8 126 28.9
KYPN 42 M D Y 28 Y Y 3 N Y Y N N 19500 7.1 143000 112 48 0.7 129 24.2
KMR 35 M D Y 7 Y 2 Y Y Y N Y 19100 4.3 53000 266 55 1.3 131 5.9
MTI 39 M D y 21 y N 0 y N N N Y 17200 12.5 272000 95 38 2.9 130 31.9
MHN 42 M D Y 28 Y Y 3 N N Y Y Y 15100 7.3 164000 72 59 3 125 14.8
NGRJ 30 M D Y 10 Y Y 2 Y N N N Y 3500 9.3 50000 108 28 0.9 132 26
NSHM 44 M D Y 30 Y Y 3 Y Y Y N Y 23000 8.4 85000 75 52 1.1 129 33.1
PBU 18 M D y 25 y y 1 N N N N Y 14500 8.9 46000 104 28 0.9 132 11.6
RJKTH 35 M D Y 28 N N 0 N Y Y N Y 23900 6.9 70000 69 56 1.4 124 12.7
RMH 40 M D Y 28 Y Y 2 N N Y N N 17900 8 75000 96 55 1.7 137 24.7
RVI 48 M D Y 10 Y Y 3 Y Y Y N N 23000 7.5 60000 78 108 4.5 125 23.5
SVRJ 57 M D Y 25 Y Y 3 Y Y Y N N 19000 12.2 50000 100 199 3.8 136 26.2
SGNM 48 M D Y 20 Y Y 2 Y N N N Y 580 9.9 55000 75 96 3.4 115 23.5
SVLU 54 M D Y 21 Y Y 3 Y N Y N y 18700 9.8 250000 142 64 1 125 24
TSM 52 M D Y 28 Y Y 2 Y N Y N N 9100 9.2 97000 95 24 0.9 130 9.1
VSDN 64 M D Y 21 Y N 0 N Y N Y Y 12000 9.4 176000 78 45 1 116 38
VLU 45 M D Y 14 Y Y 1 Y N N N N 9800 7.6 190000 254 128 3.9 130 14.4
SRA 19 F D/T Y 20 Y Y 2 N N N N y 15600 10.1 125000 110 28 0.9 138 25
SYD 54 M D/T Y 25 Y N 0 N N N N y 14,500 13 85,000 78 40 1.1 136 26
N
am
e
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T
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bu
m
in
PT IN
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R
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P
Blood Cx Urine Cx Other ID
M
D
F
C
TP
M
EL
D
S
IR
S
SO
FA
D
IA
LY
SI
S
M
O
F 
AT
A
D
M
AM 256 296 6 3.1 19 1.7 24 2 Y N 11 21 Y 7 N N
AN 135 75 5.7 3.2 23 1.9 48 2 N N 67.3 12 25 Y 4 N N
ANDRAI 135 95 5.9 2.9 22 1.7 6 0 N N 50.6 11 21 Y 3 N N
BN 197 220 5.4 2.6 29 2.9 48 2 Y y N CELLULITIS 14 37 Y 6 Y Y
CS 156 85 5.8 3.2 20.9 1.6 96 2 Y y N KLEBSIELLA 66 10 25 Y 7 N N
EI 126 112 5.4 2.2 20 1.7 6 2 n n 51.1 13 26 N 5 N N
ER 134 120 5.2 2.4 23 1.8 96 1 Y y Y 66.2 11 23 Y 7 N N
GS 72 24 6 1.9 19 1.5 24 2 Y y N
PERI
ANALABCESS 44.2 12 20 Y 5 N N
HI 98 196 5 2.7 20.9 1.74 24 1 Y N 66.1 11 23 N 4 N N
JPH 56 39 6.6 3.7 20.3 1.94 24 2 Y N 43 11 24 Y 5 N N
KN 124 188 5.4 2.9 23.9 2.22 48 2 Y N 59.1 12 23 N 3 N N
KPN 148 76 6.2 3.4 20.2 1.56 24 2 N N 40.2 9 19 N 3 N N
MI 192 151 6.5 3.8 19 1.5 24 1 N N 9 20 N 3 N N
NA 247 346 5.4 2.6 25 2.6 96 2 0 N 11 30 Y 6 N N
PL 196 235 5.8 2.9 20 1.8 24 2 N N 10 23 N 4 N N
RU 148 96 5.3 2.6 26 2.7 96 2 Y N 90.4 12 32 Y 10 Y Y
RA 80 75 5.9 2.9 20 1.7 24 1 N N 40.4 12 20 Y 6 N N
RMN 45 35 5.2 2.5 25 2.3 48 4 Y N 13 29 N 6 N N
RMSH 78 62 5.1 1.8 26.8 2.08 48 2 Y y n KLEBSIELLA 69.7 13 21 Y 3 N N
SVN 135 92 6.1 3.3 25 2.2 6 2 Y y N CELLULITIS 61.6 13 29 Y 7 N N
SKR 170 230 6.3 3.4 17 1.5 46 2 N N 11 18 N 4 N N
SLM 78 134 5.8 2.6 20 1.6 6 0 N N 11 21 N 3 N N
SRYA 170 132 5.8 0 26 2.2 24 3 N N 67 10 24 N 4 N N
VKTN 137 61 6.6 2.5 26.5 2.16 24 2 Y N 77.8 12 25 Y 4 N N
VKTH 75 38 5.4 2.3 19 1.5 24 2 N y Y 51.8 13 26 Y 5 N N
AUTN 138 123 3.6 1.9 25.9 2.01 96 1 N N 74 13 24 Y 8 N N
CJVI 100 62 5.2 3 23 1.78 94 2 Y N 75 11 26 Y 6 N N
KYPN 143 73 6.6 3.5 29 2.7 24 2 Y N 102 12 39 y 7 y N
KMR 56 42 6 3.1 31.5 2.38 96 Y N 93.3 12 25 Y 7 Y N
MTI 249 118 6 2.3 22.3 1.91 96 2 y n 78 12 37 y 6 y y
MHN 115 125 6 3.2 26.9 2.22 96 2 Y y n KLEBSIELLA 83.8 12 36 Y 6 Y N
NGRJ 250 225 5 2.9 42.5 4.02 96 2 Y y Y PSEUDOMONAS 13 34 Y 9 N Y
NSHM 171 66 5.2 3.1 20 1.9 96 2 y y N CONG 86 14 27 Y 8 Y N
PBU 237 298 5.3 2.8 24 2 48 0 N N 11 23 N 4 N N
RJKTH 95 82 5.2 2.6 34 2.9 48 1 Y y Y KLEBSIELLA 113 12 31 Y 9 Y Y
RMH 104 51 5.5 3.1 19 1.5 98 Y N 52.3 12 Y 8 Y N
RVI 128 147 5.3 2.3 45 4.5 96 Y y Y KLEBSIELLA 123 14 48 Y 14 Y Y
SVRJ 310 1642 5.2 3 23 1.9 96 3 N N 77 12 39 Y 13 Y Y
SGNM 168 190 5.7 2.8 36 3.5 96 2 Y N 128 14 44 Y 7 Y Y
SVLU 104 37 5.6 2.2 24 2 238 2 Y y N PNEUMONIA 75.2 14 26 Y 9 N y
TSM 186 121 6 3.9 24 1.9 24 3 Y N 64.3 12 22 Y 6 Y N
VSDN 256 240 5.3 2.9 38 3.86 96 3 Y N 13 35 Y 6 Y N
VLU 58 80 5.6 2.6 24 2 96 0 N y N PNEUMONIA 9 37 Y 7 Y Y
SRA 250 200 5.5 2.9 27 2.5 96 2 N N 13 29 Y 6 N n
SYD 350 458 5.5 3 28 3 96 2 N N 12 29 Y 6 N Y
Name MOF aft adm Etiology acute cause No of organ failure PAST H/O CLD CAUSE OFDEATH
AM N HEP B HEP B 1 N
AN N ALCOHOL ALCOHOL 1 N
ANDRAI N ALCOHOL ALCOHOL 1 N
BN y HEP B HEP B 3 Y
CS N ALCOHOL ALCOHOL 1 N
EI N ALCOHOL ALCOHOL 1 N
ER N ALCOHOL ALCOHOL 1 Y
GS N ALCOHOL ALCOHOL 1 N
HI N ALCOHOL ALCOHOL 1 N
JPH N ALCOHOL ALCOHOL 1 N
KN N ALCOHOL ALCOHOL 0 N
KPN N ALCOHOL ALCOHOL 0 N
MI N HEP B HEP B 0 N
NA N AUTOIMMUNE CRYPTO 2 Y
PL N CRYPTO DILI 1 N
RU Y ALCOHOL ALCOHOL 2 N
RA N AUTOIMMUNE CRYPTO 0 N
RMN N HCV CRYPTO 1 Y
RMSH N ALCOHOL ALCOHOL 0 N
SVN N ALCOHOL CRYPTO 1 Y
SKR N HEP B HEP B 0 Y
SLM N ALCOHOL ALCOHOL 0 N
SRYA N ALCOHOL HEV 0 N
VKTN N HEP B ALCOHOL 1 N
VKTH N ALCOHOL ALCOHOL 1 N
AUTN Y ALCOHOL ALCOHOL 3 Y MOF
CJVI Y ALCOHOL ALCOHOL 3 N ICH
KYPN Y ALCOHOL ALCOHOL 4 N MOF
KMR N ALCOHOL ALCOHOL 3 N MOF
MTI y ALCOHOL ALCOHOL 4 Y MOF
MHN Y ALCOHOL ALCOHOL 3 N MOF
NGRJ Y HEP B HEP B 3 Y MOF
NSHM Y ALCOHOL ALCOHOL 6 N MOF
PBU N WILSON CRYPTO 1 Y ICH
RJKTH Y ALCOHOL ALCOHOL 3 N MOF
RMH Y ALCOHOL ALCOHOL 3 Y MOF
RVI Y ALCOHOL ALCOHOL 2 N MOF
SVRJ Y ALCOHOL HEV 4 N MOF
SGNM Y ALCOHOL CRYPTO 4 N MOF
SVLU Y Hep B alcohol 4 N MOF
TSM Y ALCOHOL CRYPTO 3 Y MOF
VSDN Y HEP B HEP B 3 Y MOF
VLU Y HCV CRYPTO 2 N MOF
SRA Y WILSON DILI 2 N MOF
SYD y Hep B HEV 2 Y MOF







